Management of de novo metastatic hormone-sensitive prostate cancer: A comprehensive report of a single-center experience.

PLoS One · 2022 · PMC9390935 · PMID 35984843

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

We conducted a separate PSA PFS analysis among a subset of evaluable patients which showed a trend towards longer PSA PFS with NHAs compared to docetaxel.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.